Method for diagnosing cancers expressing the HER2 receptor or its truncated variants
Details for Australian Patent Application No. 2009265921 (hide)
International Classifications
Event Publications
13 January 2011 PCT application entered the National Phase
PCT publication WO2010/000565 Priority application(s): WO2010/000565
7 June 2012 Amendment Made
The nature of the amendment is: Amend the priority details to read P200801652 02 Jun 2008 ES 2009278070 Unilever PLC The nature of the amendment is: Amend the name of the inventor to read Restrepo, Nicolas E.; Shutak, Alexander Kingston; Regan, Joseph James; Casbarro, Bruce; Tsaur, Liang Sheng and Subramanian, Vivek
30 August 2012 Section 223 Application Allowed
Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats; Fundacio Privada Institut d'Investigacio Oncologica de Vall Hebron; Fundacio Privada Institut de Recerca Hospital Universitari Vall Hebron The time in which to claim the convention priority date has been extended to 02 Jul 2009 . Address for service in Australia - Shelston IP Level 21 60 Margaret Street Sydney NSW 2000 Extensions of Time, Section 223 2012
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2009265940-Sunscreen composite particles dispersed in water-in-oil cosmetic compositions
2009265919-Device for connecting pipelines which are subject to axial changes in length
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser